Why your asthma inhaler is so expensive (in the US)
5 hours ago
- #Healthcare Costs
- #Drug Pricing
- #Pharmaceutical Industry
- Approximately 10% of the U.S. population has asthma, with effective but expensive treatments due to factors like the ozone hole, patents, drug pricing systems, and pharmaceutical company profits.
- Primary asthma treatments include β2-agonists (e.g., albuterol) and corticosteroids (e.g., fluticasone), often delivered via metered-dose inhalers (MDIs), with patents on the drugs themselves long expired.
- The shift from ozone-depleting chlorofluorocarbon (CFC) propellants to hydrofluoroalkane (HFA) propellants in inhalers led to new patents, allowing manufacturers to charge high brand-name prices again.
- Pharmacy benefit managers (PBMs) negotiate drug prices and formularies, but their incentives may not align with patients', leading to higher out-of-pocket costs despite rebates from manufacturers.
- GlaxoSmithKline (GSK) discontinued Flovent HFA and launched an authorized generic via Prasco, avoiding Medicaid rebate caps and removing discounts, which increased costs for patients.
- Patents are extended through strategies like chiral switches (e.g., levalbuterol from albuterol), prodrugs (e.g., desloratadine from loratadine), and additional indications (e.g., semaglutide for weight loss).
- A generic fluticasone HFA inhaler was approved in March 2026, with potential for more competition and price drops after a 180-day exclusivity period ends.
- The U.S. drug pricing system is opaque, often resulting in higher prices than in other countries, with burdens on patients, especially those with less comprehensive insurance.